A detailed history of Lazard Asset Management LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 378,339 shares of XERS stock, worth $1.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
378,339
Previous 636,244 40.54%
Holding current value
$1.16 Million
Previous $1.43 Million 24.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.06 - $2.96 $531,284 - $763,398
-257,905 Reduced 40.54%
378,339 $1.08 Million
Q2 2024

Aug 14, 2024

BUY
$1.7 - $2.45 $366,786 - $528,604
215,757 Added 51.31%
636,244 $1.43 Million
Q1 2024

May 14, 2024

BUY
$2.04 - $3.22 $34,014 - $53,690
16,674 Added 4.13%
420,487 $929,000
Q4 2023

Feb 14, 2024

BUY
$1.47 - $2.36 $129,839 - $208,449
88,326 Added 28.0%
403,813 $948,000
Q3 2023

Nov 14, 2023

BUY
$1.8 - $2.69 $342,088 - $511,231
190,049 Added 151.51%
315,487 $586,000
Q2 2023

Aug 14, 2023

SELL
$1.82 - $2.98 $298,501 - $488,755
-164,012 Reduced 56.66%
125,438 $328,000
Q1 2023

May 15, 2023

SELL
$1.03 - $1.63 $58,639 - $92,799
-56,932 Reduced 16.44%
289,450 $471,000
Q4 2022

Feb 14, 2023

SELL
$1.14 - $1.65 $69,798 - $101,024
-61,227 Reduced 15.02%
346,382 $460,000
Q3 2022

Nov 14, 2022

SELL
$1.37 - $1.93 $159,858 - $225,202
-116,685 Reduced 22.26%
407,609 $635,000
Q2 2022

Aug 09, 2022

SELL
$1.48 - $2.64 $2.71 Million - $4.83 Million
-1,828,305 Reduced 77.71%
524,294 $807,000
Q1 2022

May 13, 2022

SELL
$2.0 - $2.87 $256,152 - $367,578
-128,076 Reduced 5.16%
2,352,599 $6.02 Million
Q4 2021

Feb 09, 2022

BUY
$1.8 - $2.93 $4.47 Million - $7.27 Million
2,480,675 New
2,480,675 $7.27 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $416M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.